LOGIN  |  REGISTER
Viking Therapeutics
Cue Biopharma

Sonida Senior Living to Participate in the Morgan Stanley 8th Annual CRE Conference

February 06, 2025 | Last Trade: US$26.05 0.11 -0.42

DALLAS / Feb 06, 2025 / Business Wire / Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in senior living communities, announced today that Brandon Ribar, President & Chief Executive Officer, Kevin Detz, Chief Financial Officer and Max Levy, Chief Investment Officer, will participate in Morgan Stanley’s Annual Commercial Real Estate Conference on Wednesday, February 19th and Thursday, February 20th at the Morgan Stanley Headquarters in New York City.

Management will be available for one-on-one meetings with institutional investors during the conference. To schedule a meeting, please contact your bank representative.

In addition, Mr. Ribar is scheduled to participate in a moderated panel discussion entitled “Longevity and Senior Living,” on Wednesday, February 19th from 10:15 a.m. – 10:55 a.m. EST.

About Sonida

Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 94 senior housing communities in 20 states with an aggregate capacity of over 10,000 residents, including 81 communities which the Company owns (including eight communities in which the Company owns varying interests through two separate joint ventures), and 13 communities that the Company manages on behalf of a third-party.

For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, X or LinkedIn. 

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page